AFFECTIVE AND COGNITIVE CONSEQUENCES OF ECT
AFFECTIVE AND COGNITIVE CONSEQUENCES OF ECT
批准号:
2890301
负责人:
HAROLD A. SACKEIM
金额:
$34.65万
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-08-01 至 2000-07-31
关键词:
antidepressants antipsychotic agents bipolar depression manic phase cognition electroconvulsive therapy electroencephalography gender difference human subject human therapy evaluation major depression mental disorder chemotherapy neuropsychological tests remission /regression schizophrenia seasonal affective disorder
中文摘要
关于电剂量的影响的资料很少
英文摘要
There is a paucity of information on the effects of electrical dosage in
patients who receive ECT. There is marked variability in human seizure
threshold, and in the treatment of major depression, stimulus intensity
relative to seizure threshold appears to impact substantially on the
efficacy and efficiency of ECT, as well as on cognitive side effects. We
have replicated earlier results that low dose unilateral ECT (just above
seizure threshold) is ineffective, with response rates of 28% and 18% in
two independent samples. In contrast, bilateral ECT, in both low and high
dose conditions, has resulted in a clinical response rate of ` 70%.
Unilateral ECT administered at 150% above seizure threshold has produced an
intermediate response rate (47%): clearly superior to low dose unilateral
ECT, but inferior to bilateral ECT (low and high dose). Across unilateral
and bilateral ECT conditions, higher stimulus dose appears to significantly
increase the speed of clinical response. There is also now evidence that
it is the degree to which electrical dose exceeds seizure threshold, and
not the absolute dose given, that impacts on efficacy and side effect
profiles. In recent years there has been flowing uncertainty about the
relative efficacy of unilateral ECT. These new findings indicate that
depending on dosage factors, the efficacy of unilateral ECT can vary
markedly. The flow and ceiling for such effects are unknown, and dose-
response functions for unilateral ECT need to be determined. This is of
particular clinical relevance given the superiority of unilateral ECT, at
traditional dose levels, in cognitive side effects. This proposed study
will use a random-assignment, double-blind, four-group design in 120
patients with major depression to compare right unilateral ECT at three
dosage levels: 50%, 150% and 450% above seizure threshold, with a
bilateral group treated at 150% above seizure threshold serving as a
standard for efficacy and side effect comparisons. The study will provide
information as to which of these unilateral ECT conditions may be preferred
in clinical practice, based on the tradeoff between efficacy and side
effects. In determining such relations, alternative measures for ECT
stimulus quantification will be evaluated, as well as new methods for dose
quantification. It is hypothesized that efficacy and objective cognitive
side effects will show incremental changes at each of the unilateral ECT
dose levels, and that the high dose unilateral condition will be equivalent
to the moderate dose bilateral condition in efficacy, but will still retain
advantages with respect to side effect profiles. In examining
neurobiological effects of stimulus dosing in unilateral ECT, it is
hypothesized that enhanced stimulus intensity results in greater anterior
(frontal) cortical changes in EEG measures, without impact on asymmetry,
and in greater ictal subcortical generalization, resulting in a steeper
acute prolactin surge and greater ictal and interictal global EEG delta
activity. This research is designed to address the questions of where in
the dosing range unilateral ECT is optimized and, when optimized, how does
this treatment compare to bilateral ECT.
期刊论文(113)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.7916/d89c88wm
发表时间:
1993-07
期刊:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子:
--
作者:
[H. Sackeim;I. Prohovnik;J. Moeller;R. Mayeux;Y. Stern;D. Devanand]
通讯作者:
H. Sackeim;I. Prohovnik;J. Moeller;R. Mayeux;Y. Stern;D. Devanand
Symptomatic predictors of ECT response in medication-nonresponsive manic patients.
药物无反应躁狂患者 ECT 反应的症状预测因素。
DOI:
--
发表时间:
1992
期刊:
The Journal of clinical psychiatry
影响因子:
--
作者:
[Schnur,DB, Mukherjee,S, Sackeim,HA, Lee,C, Roth,SD]
通讯作者:
Roth,SD
Regional cerebral blood flow in mood disorders. I. Comparison of major depressives and normal controls at rest.
情绪障碍时的局部脑血流。
DOI:
10.1001/archpsyc.1990.01810130062009
发表时间:
1990
期刊:
Archives of general psychiatry
影响因子:
--
作者:
[Sackeim,HA, Prohovnik,I, Moeller,JR, Brown,RP, Apter,S, Prudic,J, Devanand,DP, Mukherjee,S]
通讯作者:
Mukherjee,S
Asymmetry of the face at rest: size, area and emotional expression.
休息时面部的不对称:大小、面积和情绪表达。
DOI:
10.1016/s0010-9452(84)80035-0
发表时间:
1984
期刊:
Cortex; a journal devoted to the study of the nervous system and behavior
影响因子:
--
作者:
[Sackeim,HA, Weiman,AL, Forman,BD]
通讯作者:
Forman,BD
Effects of predictors of hemispheric specialization on individual differences in hemispheric activation.
半球特化预测因素对半球激活个体差异的影响。
DOI:
10.1016/0028-3932(84)90007-1
发表时间:
1984
期刊:
Neuropsychologia
影响因子:
2.6
作者:
[Sackeim,HA, Weiman,AL, Grega,DM]
通讯作者:
Grega,DM
共 78 条
Core--Clinical evaluation
-
批准号:6643687
-
项目类别:
-
资助金额:$17.72万
-
财政年份:2002
-
负责人:HAROLD A. SACKEIM
-
依托单位:
Core--Clinical evaluation
-
批准号:6480789
-
项目类别:
-
资助金额:$17.72万
-
财政年份:2001
-
负责人:HAROLD A. SACKEIM
-
依托单位:
OPTIMIZATION OF ELECTROCONVULSIVE THERAPY
-
批准号:6629282
-
项目类别:
-
资助金额:$21.41万
-
财政年份:2001
-
负责人:HAROLD A. SACKEIM
-
依托单位:
OPTIMIZATION OF ELECTROCONVULSIVE THERAPY
-
批准号:6260485
-
项目类别:
-
资助金额:$21.41万
-
财政年份:2001
-
负责人:HAROLD A. SACKEIM
-
依托单位:
OPTIMIZATION OF ELECTROCONVULSIVE THERAPY
-
批准号:6841642
-
项目类别:
-
资助金额:$21.41万
-
财政年份:2001
-
负责人:HAROLD A. SACKEIM
-
依托单位:
OPTIMIZATION OF ELECTROCONVULSIVE THERAPY
-
批准号:6691744
-
项目类别:
-
资助金额:$21.41万
-
财政年份:2001
-
负责人:HAROLD A. SACKEIM
-
依托单位:
OPTIMIZATION OF ELECTROCONVULSIVE THERAPY
-
批准号:6499375
-
项目类别:
-
资助金额:$21.41万
-
财政年份:2001
-
负责人:HAROLD A. SACKEIM
-
依托单位:
Core--Clinical evaluation
-
批准号:6339877
-
项目类别:
-
资助金额:$26.01万
-
财政年份:2000
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CEREBROVASCULAR ABNORMALITIES IN LATE ONSET DEPRESSION
-
批准号:6343721
-
项目类别:
-
资助金额:$21.32万
-
财政年份:1997
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CONTINUATION PHARMACOTHERAPY FOLLOWING ECT
-
批准号:2890927
-
项目类别:
-
资助金额:$8.4万
-
财政年份:1997
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CEREBROVASCULAR ABNORMALITIES IN LATE ONSET DEPRESSION
-
批准号:2034705
-
项目类别:
-
资助金额:$38.91万
-
财政年份:1997
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CEREBROVASCULAR ABNORMALITIES IN LATE ONSET DEPRESSION
-
批准号:2858040
-
项目类别:
-
资助金额:$45.41万
-
财政年份:1997
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CEREBROVASCULAR ABNORMALITIES IN LATE ONSET DEPRESSION
-
批准号:6139396
-
项目类别:
-
资助金额:$45.83万
-
财政年份:1997
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CONTINUATION PHARMACOTHERAPY FOLLOWING ECT
-
批准号:2675622
-
项目类别:
-
资助金额:$15.75万
-
财政年份:1997
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CONTINUATION PHARMACOTHERAPY FOLLOWING ECT
-
批准号:2035644
-
项目类别:
-
资助金额:$15.37万
-
财政年份:1997
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CEREBROVASCULAR ABNORMALITIES IN LATE ONSET DEPRESSION
-
批准号:2635526
-
项目类别:
-
资助金额:$39.31万
-
财政年份:1997
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CONTINUATION PHARMACOTHERAPY FOLLOWING ECT
-
批准号:2247800
-
项目类别:
-
资助金额:$19.12万
-
财政年份:1992
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CONTINUATION PHARMACOTHERAPY FOLLOWING ECT
-
批准号:2247799
-
项目类别:
-
资助金额:$18.3万
-
财政年份:1992
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CONTINUATION PHARMACOTHERAPY FOLLOWING ECT
-
批准号:3387516
-
项目类别:
-
资助金额:$18.24万
-
财政年份:1992
-
负责人:HAROLD A. SACKEIM
-
依托单位:
CONTINUATION PHARMACOTHERAPY FOLLOWING ECT
-
批准号:3387517
-
项目类别:
-
资助金额:$15.9万
-
财政年份:1992
-
负责人:HAROLD A. SACKEIM
-
依托单位:
海外基金